Access to Medicine Index homepage
2018 Index finds progress being led by a handful of companies, including in pricing and R&D
6th Access to Medicine Index: latest analysis of pharma action.
The Index reports how 20 pharmaceutical companies make medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries.
Five companies are carrying out 63% of the most urgently needed R&D projects
Pharmaceutical R&D priorities have been identified for people in low- and middle-income countries. Companies are responding: priority R&D accounts for a fifth of all R&D projects analysed.
Most key on-patent products have access initiatives, but these are limited in reach
The Index has identified 53 products that are critical candidates for companies’ access initiatives: they are on-patent, first-line therapies seen as essential for all healthcare systems.
News related to the Access to Medicine Index
"There have been massive improvements in global health in the past decades, with all major pharmaceutical companies taking action. To close the gaps that remain, a greater diversity of companies must get involved and stay engaged."
Jayasree K. Iyer
Executive Director Access to Medicine Foundation
View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.